TheraRadar
Landscape / CNS
Page updated Jul 4, 2026 · using data updated on Jun 28, 2026

Alzheimer's Disease Clinical Trial Landscape

Alzheimer's Disease is a progressive neurodegenerative condition and the most common cause of dementia, primarily affecting older adults and characterized by cognitive decline. The clinical trial landscape for Alzheimer's Disease demonstrates substantial research activity, with 1,498 trials registered since 2008, and 367 trials currently active.

The majority of active trials are in Phase 2 (199 trials), followed by Phase 1 (105 trials), suggesting a strong focus on early-stage therapeutic development. Phase 3 trials account for 84 active trials, while Phase 4 has 35.

Eli Lilly leads industry sponsorship of active trials with 10, followed by Bristol-Myers Squibb with 8, Roche with 6, Luye Pharma Group Ltd. with 5, and ACADIA Pharmaceuticals Inc. with 4. The high number of Phase 2 trials relative to Phase 3 suggests a pipeline still heavily invested in exploring novel therapeutic approaches.

Trial activity

376 active / 1,519 total since 2008
Active by phase 83 Ph3 / 290 188 Ph2 / 668 67 Ph1 / 420 38 Ph4 / 141

Competitive Intelligence

This Alzheimer's Disease competitive landscape maps 15 companies against 13 mechanisms of action (MOA) across 19 active drug-development programs. Each cell is the lead program for a company–mechanism pair — its trial phase, modality, combination, and nearest readout. Read down a column to see who is competing on the same mechanism in Alzheimer's Disease, across a row to see one company's mechanistic spread, and click any cell for the full program list and trial links.

Beta 15 companies 13 mechanisms 19 programs mapped 2 lowTrust (11%) ⏰ 4 due ≤6 mo click any cell → asset tearsheet
At a glance

Alzheimer's Disease shows 19 programs across 15 companies and 13 mechanisms. The most contested mechanism is M1/M4 muscarinic agonist (12 programs).

Key findings
  • 50% of M1/M4 muscarinic agonist programs (6 of 12) are combos with novel agents — class-extension work, not class-validation.
  • Top 3 mechanisms (Anti-amyloid (mAb), M1/M4 muscarinic agonist, Undisclosed target) account for ~28% of programs — class concentration is low.
  • Bristol-Myers Squibb runs 12 programs — the deepest pipeline in this view.
  • 25 hot readouts in next 6 months — most imminent: Ono (Undisclosed target).
  • 15 trials are stale (overdue without status change) — possible class-maturity inflection or operational issue.
  • 47 single-program mechanisms in the long tail — 28 are Ph2+ first-in-class first-mover bets.
  • 41 NME candidates in the long tail.
  • Most-novel-of-novel: Actinogen Medical 11beta-HSD1 (Ph2+Ph3) — first-in-class within scope + NME candidate.

Forward catalysts next 18 months⏰ 4 due ≤6 mo

Nearest first. ⚖ Confirmed FDA PDUFA dates (curated calendar, primary sources) and 📅 estimated readouts (ClinicalTrials.gov primaryCompletionDate — a timing proxy, not a confirmed action date). Red = due within 6 months.

Company × Mechanism

Each cell = a company’s most-advanced program in that mechanism. Click for the asset tearsheet.
Unverified (lowTrust) cells:
Ph1 Ph2 Ph3 Ph4 ⚠ lowTrust +combo
Select & Focus Pro → 🔒 Transpose, filtering, selection & export are Pro (search & sort are free) — start a free trial, or try them free on our showcase →
M1/M4 muscarinic agonist
Anti-amyloid (mAb)
Undisclosed target
Anti-amyloid (BBB-shuttle)
Autologous adipose MSC
Anti-tau (mAb)
Tau ASO
5-HT2A inverse agonist
Anti-sortilin (progranulin)
D2/5-HT modulator
Autologous NK cell
TAU
Tau siRNA
Bristol-Myers Squibb
Eli Lilly
Roche / Genentech
Eisai
Regeneration Biomedical
ACADIA
GSK
Intra-Cellular Therapies
Keymed
MapLight
NKGen
Ono
Alnylam
Merck & Co.
Novartis

Phase 3 leaders · most advanced

  1. active Annovis Bio Inc. NCT06709014
  2. recruiting Karuna Therapeutics, Inc., a Bristol Myers Squibb company NCT05980949
  3. recruiting Karuna Therapeutics, Inc., a Bristol Myers Squibb company NCT06126224
  4. recruiting Bristol-Myers Squibb NCT06947941
  5. active Eli Lilly and Company NCT05508789

Beyond the grid Beta

What the matrix leaves out — rare mechanisms with only one player, small & emerging sponsors, and programs we haven’t classified yet.

Single-company mechanisms — BD white space 8 found

Mechanisms only ONE company is pursuing in this indication — the uncrowded / first-in-class bets the matrix cap hides. ⚡ first-in-class · ⚠ unverified mechanism. ⚡ first-in-class is computed across 61 mapped landscapes — scope-limited, not a global claim.
⚡ first-in-class · 🌱 first-in-indication · 🆕 NME candidate · ✅ AI-classified + verified · ⚙️ AI-classified, unverified · first-in-class computed across 61 mapped landscapes
Single-program mechanisms (47) — one program each — earliest-stage, sorted by phase
PhaseMechanismCompanyModalityReadoutTrial
Ph2+Ph3 11beta-HSD1 ⚡ 🌱 🆕 Actinogen Medical ⏰ 4Q26 NCT06125951
Ph3 5-HT6 antagonist ⚡ 🌱 🆕 Suven Life Sciences Limit… Oral ⏰ 4Q26 NCT05397639
Ph3 APP/α-syn translation inhibitor 🌱 🆕 Annovis Bio Oral 4Q27 NCT06709014
Ph3 BCR-ABL ⚡ 🌱 KeifeRx Oral 4Q25 NCT05143528
Ph3 Botanical extract 🌱 🆕 ⚙️ Sichuan Jishengtang Oral ⏰ 3Q26 NCT06534723
Ph3 Botanical extract (Neuroaid) ⚡ 🌱 🆕 ⚙️ Moleac Pte 1Q29 NCT07191028
Ph2+Ph3 Cannabinoid (CB1) ⚡ 🌱 Benuvia Oral 2Q28 NCT07422311
Ph3 Histamine/serotonin/cholinesterase ⚡ 🌱 Bigespas 2Q27 NCT07251023
Ph3 Medium-chain triglyceride ⚡ 🌱 🆕 Cerecin Oral 4Q28 NCT05809908
Ph2+Ph3 MELATONIN RECEPTOR ⚡ 🌱 🆕 Neurim 2Q25 NCT05267535
Ph3 Metabolic activator ⚡ 🌱 🆕 ⚙️ ScandiBio Therapeutics AB ⏰ 3Q26 NCT07062198
Ph2+Ph3 NMDA modulator ⚡ 🌱 🆕 Exciva 1Q29 NCT07284472
Ph2+Ph3 NMDA RECEPTOR ⚡ 🌱 Wanbangde Pharmaceutical … 3Q28 NCT07066826
Ph3 PDE5 inhibitor ⚡ 🌱 🆕 AriBio Oral ⏰ 2Q26 NCT05531526
Ph2+Ph3 PPARδ/γ agonist ⚡ 🌱 🆕 T3D Oral 2Q31 NCT06964230
Ph3 Tau PET tracer ⚡ 🌱 🆕 ⚙️ JYAMS PET Research & Deve… Radioligand ⏰ 4Q26 NCT07422857
Ph3 Telomerase peptide vaccine ⚡ 🌱 🆕 Samsung SC 1Q28 NCT05303701
Ph3 Transthyretin ⚡ 🌱 Eidos Therapeutics, a Bri… Oral 4Q31 NCT06563895
Ph3 TRANSTHYRETIN ⚡ 🌱 🆕 Eidos Therapeutics, a Bri… 4Q37 NCT07116473
Ph3 Tyrosine kinase (masitinib) 🌱 🆕 AB Science 4Q28 NCT05564169
Ph2 Anti-amyloid oligomer ⚡ 🌱 🆕 Acumen IV ⏰ 4Q26 NCT06335173
Ph1+Ph2 Autologous DC + Aβ peptide ⚡ 🌱 🆕 Alzamend Neuro IM 1Q28 NCT05834296
Ph2 Cannabinoid (THC) ⚡ 🌱 🆕 IGC Pharma Oral ⏰ 3Q26 NCT05543681
Ph2 CB2 agonist ⚡ 🌱 🆕 NeuroTherapia Oral 4Q25 NCT07058688
Ph1+Ph2 Donepezil (long-acting) ⚡ 🌱 ⚙️ Inventage Lab. Oral 4Q25 NCT05345509
Ph2 FAAH/MAGL inhibitor 🌱 🆕 Bristol-Myers Squibb 4Q27 NCT06808984
Ph1+Ph2 IsoLG scavenger ⚡ 🌱 🆕 MTI Oral 2Q28 NCT06432166
Ph2 MAO-B (reversible) 🌱 🆕 NeuroBiogen Oral 2Q27 NCT07027072
Ph1+Ph2 Microglia PET imaging (¹⁸F radioligand) 🌱 🆕 Ashvattha Radioligand 1Q26 NCT05395624
Ph2 MTBR ⚡ 🌱 🆕 Bristol-Myers Squibb 1Q27 NCT06268886
Ph2 NLRP3 inhibitor 🌱 🆕 Halia 2Q27 NCT07399171
Ph2 P. gingivalis gingipain ⚡ 🌱 🆕 Lighthouse 1Q29 NCT06847321
Ph2 Retinal amyloid imaging agent ⚡ 🌱 🆕 ⚙️ Amydis ⏰ 3Q26 NCT06514001
Ph2 SIGMAR2 ⚡ 🌱 🆕 Cognition 2Q27 NCT05531656
Ph2 Synaptogenic 🌱 🆕 Spinogenix Oral 4Q25 NCT06427668
Ph2 TREM2 agonist (mAb) 🌱 🆕 Novartis IV 3Q28 NCT07094516
Ph2 α7 nicotinic ACh PAM ⚡ 🌱 🆕 Merck & Co. Oral ⏰ 4Q26 NCT06721156
Ph1 AMYLOID PRECURSOR PROTEIN ⚡ 🌱 🆕 Alnylam 2Q29 NCT05231785
Ph1 Amyloid-beta and Tau ⚡ 🌱 🆕 Nuravax 2Q27 NCT07142278
Ph1 Anti-Aβ × BBB bispecific ⚡ 🌱 🆕 Akeso IV 2Q27 NCT07301502
Ph1 Anti-Aβ oligomer (mAb) ⚡ 🌱 🆕 ProMis Neurosciences IV ⏰ 4Q26 NCT06750432
Ph1 Anti-fibrin (mAb) ⚡ 🌱 🆕 Therini Bio IV ⏰ 2Q26 NCT06814730
Ph1 Anti-tau (small mol) ⚡ 🌱 🆕 ⚙️ Oligomerix ⏰ 2Q26 NCT05696483
Ph1 APOE4 ⚡ 🌱 🆕 Lexeo Gene therapy 4Q28 NCT05400330
Ph1 DYRK1A inhibitor ⚡ 🌱 🆕 Perha Oral ⏰ 2Q26 NCT06206824
Ph1 KLOTHO ⚡ 🌱 🆕 Klotho Sciences Australia 2Q26 NCT07143331
Ph1 Tau PET radioligand ⚡ 🌱 🆕 ⚙️ Eli Radiopharma ⏰ 4Q26 NCT07580703
Emerging & small-cap sponsors (13) — few programs here — partnering / M&A radar
PhaseMechanismCompanyModalityReadoutTrial
Ph1+Ph2 Tau siRNA ⚡ Arrowhead IT 2Q27 NCT07221344
Ph2 Anti-amyloid (mAb) ⚡ BeyondBio IV 3Q28 NCT06885567
Ph2 Tau ASO ⚡ Biogen IT 1Q26 NCT05399888
Ph1 Anti-Aβ oligomer (peptide) ⚡ Cenna 3Q27 NCT07568041
Ph3 TAU ⚡ CereMark Pharma 2Q28 NCT06254469
Ph1 Tau ASO ⚡ Denali IT 1Q27 NCT07328451
Ph2 Undisclosed target Elixiron Immunotherapeuti… Oral ⏰ 4Q26 NCT06745583
Ph2 Anti-tau (mAb) ⚡ Johnson & Johnson Oral ⏰ 4Q26 NCT06544616
Ph3 TAU ⚡ Lantheus 2Q27 NCT05641688
Ph2 Anti-Aβ oligomer (peptide) ⚡ PRInnovation Oral ⏰ 2Q26 NCT06182085
Ph1 🇨🇳 Anti-amyloid (mAb) ⚡ Qilu 1Q27 NCT07489599
Ph3 TAU ⚡ Sinotau Pharmaceutical Gr… Radioligand 4Q25 NCT07115238
Ph1+Ph2 Anti-tau (mAb) ⚡ Voyager IV 2Q27 NCT06874621
Unclassified programs (20) — mechanism not captured yet
PhaseMechanismCompanyModalityReadoutTrial
Ph3 Screening Study to Determine Individuals With Potential Trial E…unclassified Hoffmann-La Roche NCT07177352
Ph3 Epidemiology and Biomarker Study in Alzheimer's Diseaseunclassified Eli Lilly and Company NCT07142954
Ph3 Near-infrared Light Therapy Device for Mild-Moderate Alzheimer'…unclassified Danyang Huichuang Medical… NCT07262645
Ph3 A Pivotal Study of LIPUS-Brain in Patients With Early Alzheimer…unclassified Sound Wave Innovation CO.… NCT05983575
Ph1+Ph2 NSC001unclassified NSC-Therapeutics NCT06995573
Ph2 12 cm2 - 2 Active DMTS Patches, 6 cm2 - 1 Active and 1 Placebo …unclassified Teikoku Pharma USA, Inc. NCT06052254
Ph1+Ph2 Placebo (Study Part 1a), ACI-24.060 at Dose A in Study Part 1a,…unclassified AC Immune SA NCT05462106
Ph2 TTYP01 tables 60mg, TTYP01 tables 90mg, TTYP01 tables 0mgunclassified Shanghai Auzone Biologica… NCT07252440
Ph2 Plans4Care: Personalized Dementia Care on Demandunclassified Plans4Care Inc NCT07115251
Ph2 EX039, Placebounclassified Excelsior NCT05413655
Ph2 Preventing Medication Mismanagement in People Living with Demen…unclassified HiDO Technologies NCT06691256
Ph1+Ph2 PrimePro™/ PrimeMSK™unclassified Thomas Advanced Medical L… NCT04684602
Ph1+Ph2 ABBV-1758, Placebo for ABBV-1758, ABBV-1758unclassified AbbVie NCT07599670
Ph2 TML-6unclassified Merry Life Biomedical Co.… NCT07612150
Ph2 Drug: [18F]F-AraG (PET tracer)unclassified CellSight Technologies, I… NCT07611357
Ph2 Mivelsiran, Placebounclassified Alnylam Pharmaceuticals NCT07636811
Ph1 AS-S603, Placebounclassified Amyloid Solution Inc NCT06786676
Ph1 Door-Through-Door Companion Rideshare Technology for Individual…unclassified Onward Health, Inc NCT06850870
Ph1 Diprivan (propofol), Astra-Zenecaunclassified Nyree Penn NCT06644573
Ph1 BnH-015B 5 mg, BnH-015B 10 mg, BnH-015B 20 mgunclassified BnH Research NCT06535308
Drugs in this landscape: Donanemab · Lecanemab IV

Sponsor activity

Who is running trials now — green active, blue completed, red failed/terminated.

Sorted by active Active Done Failed
Eli Lilly 11 28 6
Bristol-Myers Squibb 8 11 1
Roche 6 20 10
ACADIA Pharmaceuticals Inc. 4 3 1
Luye Pharma Group Ltd. 4 1 0
Karuna Therapeutics, Inc., a Bristol Myers Squibb company 4 0 0
Eisai Inc. 3 11 2
Green Valley (Shanghai) Pharmaceuticals Co., Ltd. 3 0 1
Alnylam Pharmaceuticals 3 0 0
Regeneration Biomedical, Inc. 3 0 0
Merck 2 18 7
Novartis 2 17 4
GSK 2 10 4
Intra-Cellular Therapies, Inc. 2 1 1
Denali Therapeutics Inc. 2 1 0

All 15 active Alzheimer's Disease sponsors

Unlock the remaining 7 sponsors with active / completed / failed counts — sortable and exportable.

Unlock with Pro

How the field has grown

New-trial starts peaked in 2025 (101 registered). The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (166 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.

New trials started by year

2016
74
2017
79
2018
79
2019
78
2020
66
2021
89
2022
92
2023
81
2024
96
2025
101
2026
68

TheraRadar.com

Median Phase 3 enrollment by start year

2016 (12)
291
2017 (11)
421
2018 (20)
225
2019 (9)
493
2020 (15)
184
2021 (15)
423
2022 (21)
240
2023 (12)
350
2024 (16)
280
2025 (21)
450
2026 (14)
321

TheraRadar.com

Full trial pipeline

Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.

NCT06709014 ACTIVE NOT RECRUITING
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
Annovis Bio Inc. n=760
NCT07583979 NOT YET RECRUITING
Electroacupuncture for Cognitive Toxicity in Cancer Survivors: Assessing Implementation, Cost, and Effectiveness for Integration
National Cancer Centre, Singapore n=168
NCT07084831 NOT YET RECRUITING
A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia
European Group for Research In Schizophrenia n=171
NCT05980949 RECRUITING
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company n=800
NCT06126224 RECRUITING
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company n=500
NCT06947941 RECRUITING
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
Bristol-Myers Squibb n=325
NCT05508789 ACTIVE NOT RECRUITING
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
Eli Lilly and Company n=1,500
NCT07170150 RECRUITING
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Hoffmann-La Roche n=800
NCT06937229 RECRUITING
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
Bristol-Myers Squibb n=600
NCT06976216 RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Bristol-Myers Squibb n=586
NCT07571161 RECRUITING
Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease
Eli Lilly and Company n=140
NCT07177352 RECRUITING
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Hoffmann-La Roche n=13,000
NCT06194799 ENROLLING BY INVITATION
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
ACADIA Pharmaceuticals Inc. n=752
NCT05511363 RECRUITING
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company n=410
NCT07169578 RECRUITING
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Hoffmann-La Roche n=800
NCT06976203 RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Bristol-Myers Squibb n=586
NCT05230758 RECRUITING
Effect of Metformin on Behaviour and the Brain in Children Treated for a Brain Tumour
Donald Mabbott n=140
NCT07011745 RECRUITING
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
Bristol-Myers Squibb n=352
NCT06585787 RECRUITING
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company n=406
NCT07011732 RECRUITING
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Bristol-Myers Squibb n=352
NCT05641688 RECRUITING
[18F]PI-2620 Phase 3 Histopathological Study
Lantheus Biosciences Ltd. n=200
NCT06125951 ACTIVE NOT RECRUITING
Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease
Actinogen Medical n=247
NCT07095465 ENROLLING BY INVITATION
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
ACADIA Pharmaceuticals Inc. n=126
NCT04570085 RECRUITING
Effect of CAFfeine on Cognition in Alzheimer's Disease
University Hospital, Lille n=248
NCT07284472 RECRUITING
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
Exciva GmbH n=300
NCT06159673 RECRUITING
ACP-204 in Adults With Alzheimer's Disease Psychosis
ACADIA Pharmaceuticals Inc. n=1,074
NCT03887455 ACTIVE NOT RECRUITING
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
Eisai Inc. n=1,906
NCT04098666 ACTIVE NOT RECRUITING
Metformin in Alzheimer's Dementia Prevention
Columbia University n=326
NCT07284316 ACTIVE NOT RECRUITING
Effect of a Multidomain Intervention Plus Turmeric on the Prevention of Cognitive Decline in People Over 55 Years of Age With Insulin Resistance.
Instituto Mexicano del Seguro Social n=100
NCT03804229 ACTIVE NOT RECRUITING
Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia
Capital Medical University n=707
NCT04468659 ACTIVE NOT RECRUITING
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
Eisai Inc. n=1,400
NCT06384573 ACTIVE NOT RECRUITING
DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
Washington University School of Medicine n=40
NCT07083154 RECRUITING
GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School n=420
NCT07422311 NOT YET RECRUITING
To Evaluate the Efficacy, Safety, and Tolerability of Dronabinol Oral Solution for Agitation in Patients With Alzheimer's Disease
Benuvia Therapeutics Inc. n=140
NCT05303701 NOT YET RECRUITING
GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)
Samsung Pharmaceutical Co., Ltd. n=750
NCT07422857 RECRUITING
Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function
JYAMS PET Research & Development Limited n=316
NCT04661280 RECRUITING
Donepezil Versus Non-drug Treatment in Alzheimer's Disease.
Assistance Publique - Hôpitaux de Paris n=240
NCT06647498 RECRUITING
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Washington University School of Medicine n=280
NCT05269394 ACTIVE NOT RECRUITING
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
Washington University School of Medicine n=197
NCT05552157 RECRUITING
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Washington University School of Medicine n=280
NCT01760005 ACTIVE NOT RECRUITING
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
Washington University School of Medicine n=490
NCT07142954 RECRUITING
Epidemiology and Biomarker Study in Alzheimer's Disease
Eli Lilly and Company n=3,400
NCT07062198 RECRUITING
Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease
ScandiBio Therapeutics AB n=845
NCT04516057 RECRUITING
Nabilone for Agitation Blinded Intervention Trial
Sunnybrook Health Sciences Centre n=112
NCT03860857 RECRUITING
Biomarker Exploration in Aging, Cognition and Neurodegeneration
University of California, Irvine n=300
NCT05026866 ACTIVE NOT RECRUITING
A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Eli Lilly and Company n=2,996
NCT05397639 RECRUITING
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
Suven Life Sciences Limited n=375
NCT07234695 RECRUITING
LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau n=120
NCT07323914 RECRUITING
Clinical Analgesic Management in Dementia
Xuanwu Hospital, Beijing n=10
NCT05470816 ACTIVE NOT RECRUITING
Tranexamic Acid to Reduce Delirium After Gastrointestinal Surgery: the TRIGS-D Trial
Bayside Health n=826
NCT06534723 RECRUITING
Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney)
Sichuan Jishengtang Pharmaceutical Co., Ltd. n=570
NCT06797817 NOT YET RECRUITING
Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brain
Universidad de Almeria n=156
NCT07251023 RECRUITING
Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia
Bigespas LTD n=450
NCT05809908 NOT YET RECRUITING
Tricaprilin Phase 3 ALTER-AD (Alternative-Alzheimer Disease) Study
Cerecin n=535
NCT06653153 ACTIVE NOT RECRUITING
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
Eli Lilly and Company n=1,400
NCT05738486 ACTIVE NOT RECRUITING
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
Eli Lilly and Company n=1,175
NCT05532657 ACTIVE NOT RECRUITING
ACHIEVE Brain Health Follow-Up Study
Johns Hopkins University n=629
NCT05456503 RECRUITING
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
University of Pennsylvania n=72
NCT05564169 NOT YET RECRUITING
Masitinib in Patients With Mild Alzheimer's Disease
AB Science n=600
NCT05531526 ACTIVE NOT RECRUITING
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
AriBio Co., Ltd. n=1,535
NCT06191965 RECRUITING
MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction
Mclean Hospital n=100
NCT07191028 NOT YET RECRUITING
Alzheimer's Disease THErapy With NEuroaid II
Moleac Pte Ltd. n=350
NCT04437511 ACTIVE NOT RECRUITING
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Eli Lilly and Company n=1,736
NCT06950190 ENROLLING BY INVITATION
Evaluating Cognitive Changes on Patients in Chemotherapy (ECCPC)
Ellis Medicine n=100
NCT07115238 RECRUITING
Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD
Sinotau Pharmaceutical Group n=354
NCT06996730 NOT YET RECRUITING
A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease
Banner Health n=240
NCT06254469 RECRUITING
Visualizing Brain Proteinopathies Using [F-18]Flornaptitril-PET in the Prediction of Clinical Progression of Mild Cognitive Impairment With Either Suspected Chronic Traumatic Encephalopathy or Alzheimer's Disease
CereMark Pharma, LLC n=230
NCT07066826 NOT YET RECRUITING
Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
Wanbangde Pharmaceutical Group Co., LTD n=720
NCT07060391 NOT YET RECRUITING
A Prospective Multicenter RCT Study of Deep Jugular Lymphovenous Anastomosis in the Treatment of Alzheimer's Disease
Shanghai Jiao Tong University School of Medicine n=186
NCT05983575 ACTIVE NOT RECRUITING
A Pivotal Study of LIPUS-Brain in Patients With Early Alzheimer's Disease
Sound Wave Innovation CO., LTD. n=220
NCT06964230 NOT YET RECRUITING
A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects
T3D Therapeutics, Inc. n=376
NCT06120049 RECRUITING
[18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD
prof. dr. Koen Van Laere n=113
NCT03108846 ACTIVE NOT RECRUITING
Escitalopram for Agitation in Alzheimer's Disease
JHSPH Center for Clinical Trials n=187
NCT06702124 RECRUITING
A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease
I.R.C.C.S. Fondazione Santa Lucia n=348
NCT06530732 RECRUITING
Deep Cervical Lymphatlc-Venous Anastomosis Surgery for the Treatment of Alzheimer's Disease: A Pilot Study (DIVA Study)
Zhejiang Provincial People's Hospital n=60
NCT03848312 RECRUITING
Preventing Alzheimer's With Cognitive Training
University of South Florida n=7,600
NCT06514066 NOT YET RECRUITING
Cannabidiol's Role in Dementia Management
Hospital Pengajar Universiti Putra Malaysia n=486
NCT05267535 ACTIVE NOT RECRUITING
Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease
Neurim Pharmaceuticals Ltd. n=225
NCT03116126 ACTIVE NOT RECRUITING
Noradrenergic Add-on Therapy With Guanfacine
Imperial College London n=148
NCT05976152 RECRUITING
Effect of Butyphthalide on Cognitive Level Change After Cerebral Vascular Event-a Randomized Control Trial (Be-CLEVER)
Fudan University n=3,200
NCT04390646 RECRUITING
GnRH Therapy on Cognition in Down Syndrome
Nelly Pitteloud n=56
NCT05143528 NOT YET RECRUITING
Evaluating the Efficacy and Safety of Nilotinib BE in Subjects With Early Alzheimer's Disease
KeifeRx, LLC n=1,275
NCT07602582 RECRUITING
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
Eli Lilly and Company n=550
NCT04777396 COMPLETED
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
Novo Nordisk A/S n=1,840
NCT05891496 COMPLETED
A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease
Novo Nordisk A/S n=23
NCT06736509 TERMINATED
An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study
Axsome Therapeutics, Inc. n=139
NCT05894954 COMPLETED
Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment
Alzheimer's Prevention and Reversal Project, Inc. n=73
NCT03789760 COMPLETED
The Clinical Trial of Chinese Herbal Medicine (SaiLuoTong) Capsule
Shineway Pharmaceutical Co.,Ltd n=493
NCT04374136 TERMINATED
A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)
Alector Inc. n=119
NCT05271552 COMPLETED
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)
BioXcel Therapeutics Inc n=151
NCT04947553 COMPLETED
A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation
Axsome Therapeutics, Inc. n=456
NCT05557409 COMPLETED
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
Axsome Therapeutics, Inc. n=408
NCT04770220 COMPLETED
An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects
Alzheon Inc. n=325
NCT06304883 TERMINATED
Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
Alzheon Inc. n=163
NCT02446132 TERMINATED
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Development & Commercialization, Inc. n=1,197
NCT03121209 COMPLETED
Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial - Hemodynamics (CREST-H)
Columbia University n=392
NCT05026177 TERMINATED
Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease
Cassava Sciences, Inc. n=1,125
NCT05542953 COMPLETED
[18F]APN-1607 PET in Subjects With AD Compared to HC
APRINOIA Therapeutics n=230
NCT03446001 COMPLETED
Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment
TauRx Therapeutics Ltd n=598
NCT06566183 SUSPENDED
International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Left Ventricular Dysfunction Trial
NYU Langone Health n=1,200
NCT05256134 TERMINATED
A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)
Hoffmann-La Roche n=25
NCT04408755 TERMINATED
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Development & Commercialization, Inc. n=184
NCT04464564 TERMINATED
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Development & Commercialization, Inc. n=241
NCT04994483 COMPLETED
Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease
Cassava Sciences, Inc. n=804
NCT05575076 TERMINATED
Open-label Extension for Phase 3 Clinical Trials of Simufilam
Cassava Sciences, Inc. n=1,081
NCT05686044 COMPLETED
A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD
Annovis Bio Inc. n=351
NCT05463731 COMPLETED
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
Eli Lilly and Company n=1,667
NCT02360215 COMPLETED
Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases
NRG Oncology n=518
NCT05310071 TERMINATED
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
Biogen n=1,027
NCT04488419 COMPLETED
ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease
LeonaBio n=554
NCT04886063 TERMINATED
Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease
LeonaBio n=423
NCT01447719 COMPLETED
Autopsy Follow-up of Subjects Previously Imaged With Florbetapir F 18 (18F-AV-45) PET in Trial 18F-AV-45-A07
Avid Radiopharmaceuticals n=110
NCT03554265 COMPLETED
Brain and Gut Plasticity in Mild TBI or Post-acute COVID Syndrome Following Growth Hormone Therapy
The University of Texas Medical Branch, Galveston n=72
NCT04241068 TERMINATED
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205
Biogen n=1,696
NCT06424236 TERMINATED
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation
Washington University School of Medicine n=73
NCT05432206 COMPLETED
MEDical CANnabis for Improving Symptoms During Severe DEMentia Disorders in Long-term Care Facility in Geneva
Fondation pour l'accueil et l'hébérement des personnes âgées n=27
NCT05749939 COMPLETED
Acceptance Commitment Therapy for Caregivers of People with Memory Loss
Utah State University n=121
NCT05108922 COMPLETED
A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)
Eli Lilly and Company n=148
NCT02719327 COMPLETED
Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid
VA Office of Research and Development n=131
NCT01767909 COMPLETED
The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)
University of Southern California n=240
NCT03393520 COMPLETED
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Development & Commercialization, Inc. n=601
NCT03620981 COMPLETED
Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Co., Ltd. n=410
NCT04552041 COMPLETED
Prospekta in the Treatment of Cognitive, Behavioral and Psychiatric Disorders in Patients With Vascular Dementia.
Materia Medica Holding n=406
NCT04771299 TERMINATED
Assessing the Role of Cariprazine in Improving Cognition in Euthymic Bipolar Patients
Lakshmi N Yatham n=1
NCT03724942 COMPLETED
Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Co., Ltd. n=164
NCT04314934 COMPLETED
OLE of Phase 2b/3 Study ANAVEX2-73-AD-004
Anavex Life Sciences Corp. n=300
NCT04395339 TERMINATED
GM1 Prophylaxis for WBRT Related Cognitive Dysfunction
Sun Yat-sen University n=51
NCT05239663 TERMINATED
GM1 Prophylaxis for Post-chemotherapy Cognitive Impairment in Patients With Early Operable Breast Cancer
Sun Yat-sen University n=76
NCT03682185 COMPLETED
The Healthy Patterns Sleep Study
University of Pennsylvania n=421
NCT03486938 COMPLETED
Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease
AgeneBio n=164
NCT04374253 TERMINATED
A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)
Hoffmann-La Roche n=1,382
NCT05015803 COMPLETED
Enhanced CBTi for Older Adult Sleep and Cognition
Penn State University n=60
NCT03444870 TERMINATED
Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
Hoffmann-La Roche n=1,053
NCT04339413 TERMINATED
A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD)
Hoffmann-La Roche n=116
NCT03443973 TERMINATED
Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
Hoffmann-La Roche n=975
NCT05665088 TERMINATED
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)
BioXcel Therapeutics Inc n=13
NCT04797715 COMPLETED
Assessing Clinical Outcomes in Alzheimer's Disease Agitation
Axsome Therapeutics, Inc. n=178
NCT04669028 COMPLETED
A Phase 3 Study of NE3107 in Probable Alzheimer's Disease
BioVie Inc. n=439
NCT03594123 COMPLETED
A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Development & Commercialization, Inc. n=259
NCT01872598 COMPLETED
Masitinib in Patients With Mild to Moderate Alzheimer's Disease
AB Science n=721
NCT03548584 COMPLETED
A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Development & Commercialization, Inc. n=345
NCT03226522 COMPLETED
Addressing Dementia Via Agitation-Centered Evaluation
Axsome Therapeutics, Inc. n=366
NCT03691519 COMPLETED
Prevention of Cognitive Decline in Older Adults With Low Dha/Epa Index in Red Blood Cells
University Hospital, Toulouse n=774
NCT01278407 COMPLETED
A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase
Eisai Co., Ltd. n=142
NCT01539031 COMPLETED
Compare the Efficacy and Safety of Donepezil Hydrochloride 23 mg Treatment With Continuation of Donepezil Hydrochloride 10 mg Treatment in Japanese Subjects With Severe Alzheimer's Disease
Eisai Co., Ltd. n=351
NCT02346201 COMPLETED
Apathy in Dementia Methylphenidate Trial 2
Johns Hopkins Bloomberg School of Public Health n=200
NCT02245568 TERMINATED
Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)
TauRx Therapeutics Ltd n=913
NCT04187547 WITHDRAWN
A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease With Optional Open Label Extension
Cerecin
NCT03823404 COMPLETED
GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease
Cortexyme Inc. n=643
NCT02442765 COMPLETED
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Development & Commercialization, Inc. n=387
NCT02051608 COMPLETED
A Study of Gantenerumab in Participants With Mild Alzheimer Disease
Hoffmann-La Roche n=389
NCT04520412 SUSPENDED
A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease
Green Valley (Shanghai) Pharmaceuticals Co., Ltd. n=2,046
NCT04623242 COMPLETED
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
Washington University School of Medicine n=194
NCT02442778 COMPLETED
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Development & Commercialization, Inc. n=522
NCT01565382 COMPLETED
Evaluation of Inter-reader Reliability Using Images From Subjects With Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI)
Avid Radiopharmaceuticals n=40
NCT03986424 COMPLETED
Local Study of Akatinol Memantine in VaD in Russia
Merz Pharmaceuticals GmbH n=130
NCT03790709 COMPLETED
ANAVEX2-73 for Treatment of Early Alzheimer's Disease
Anavex Life Sciences Corp. n=509
NCT03721705 COMPLETED
Renew NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild Dementia of the Alzheimer's Type
Renew Research, LLC n=190
NCT03628391 TERMINATED
Haloperidol for Delirium in Adult Critically Ill Patients
Erasmus Medical Center n=142
NCT02913664 COMPLETED
Risk Reduction for Alzheimer's Disease
University of Texas Southwestern Medical Center n=513
NCT02164643 COMPLETED
Longitudinal Study of Brain Amyloid imaGing in MEMENTO
University Hospital, Bordeaux n=448
NCT01224106 COMPLETED
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
Hoffmann-La Roche n=799
NCT02547818 COMPLETED
Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease
AZTherapies, Inc. n=620
NCT02484547 TERMINATED
221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
Biogen n=1,643
NCT02477800 TERMINATED
221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease
Biogen n=1,653
NCT02159027 COMPLETED
Maraviroc and NeuroAIDS Pathogenesis
University of Hawaii n=48
NCT03131453 TERMINATED
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
Novartis Pharmaceuticals n=1,145
NCT01741194 COMPLETED
AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext
Cerecin n=418
NCT00951834 COMPLETED
Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer´s Disease
Charite University, Berlin, Germany n=21
NCT02565511 TERMINATED
A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
Novartis Pharmaceuticals n=480
NCT02817906 TERMINATED
ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease
Intra-Cellular Therapies, Inc. n=177
NCT03325556 COMPLETED
Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
ACADIA Pharmaceuticals Inc. n=392
NCT02916056 TERMINATED
2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)
vTv Therapeutics n=297
NCT02080364 TERMINATED
Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease
vTv Therapeutics n=880
NCT03031184 COMPLETED
Study of Mirtazapine for Agitation in Dementia
University of Sussex n=207
NCT03785067 TERMINATED
Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study
The George Institute n=1
NCT03815292 COMPLETED
Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke
Materia Medica Holding n=276
NCT03197740 COMPLETED
A Multinational, Multi-center, Randomized, Double-blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients With Alzheimer's Disease
Icure Pharmaceutical Inc. n=399
NCT02956486 TERMINATED
A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease
Eisai Co., Ltd. n=2,212
NCT01862640 COMPLETED
A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation
Otsuka Pharmaceutical Development & Commercialization, Inc. n=433
NCT01922258 COMPLETED
Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Development & Commercialization, Inc. n=270
NCT03075241 COMPLETED
Z-Drugs for Sleep Disorders in Alzheimer's Disease
Brasilia University Hospital n=62
NCT02248636 COMPLETED
Cholinesterase Inhibitor Discontinuation
VA Office of Research and Development n=72
NCT02016560 COMPLETED
Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects
Avid Radiopharmaceuticals n=383
NCT03901092 COMPLETED
A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 Positron Emission Tomography (PET) Scan Interpretation
Avid Radiopharmaceuticals n=242
NCT02516046 COMPLETED
18F-AV-1451 Autopsy Study
Avid Radiopharmaceuticals n=156
NCT03901105 COMPLETED
Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease
Avid Radiopharmaceuticals n=205
NCT02670083 TERMINATED
A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).
Hoffmann-La Roche n=813
NCT03114657 TERMINATED
A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)
Hoffmann-La Roche n=806
NCT03491150 TERMINATED
An Open-Label Crenezumab Study in Participants With Alzheimer's Disease
Hoffmann-La Roche n=149
NCT02351882 COMPLETED
Safety and Efficacy of Nabilone in Alzheimer's Disease
Sunnybrook Health Sciences Centre n=38
NCT02350127 COMPLETED
Preventing Loss of Independence Through Exercise (PLIE) in Persons With Dementia
VA Office of Research and Development n=88
NCT02586909 TERMINATED
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension
Axovant Sciences Ltd. n=1,099
NCT04318639 COMPLETED
The Combination of Donepezil and Cognitive Training for Treating Alcohol Use Disorder
VA Connecticut Healthcare System n=15
NCT04301466 COMPLETED
Efficacy and Safety of Qi Zhi Tong Luo Capsule in Vascular Cognitive Impairment
Dongzhimen Hospital, Beijing n=362
NCT02353949 TERMINATED
Investigating the Clinical Consequences of Flutemetamol-PET-scanning
University of Zurich n=11
NCT02453932 COMPLETED
Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia
Dongzhimen Hospital, Beijing n=543
NCT02783573 TERMINATED
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
AstraZeneca n=1,722
NCT02972658 TERMINATED
A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia
AstraZeneca n=421
NCT02750306 COMPLETED
Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061)
Merck Sharp & Dohme LLC n=285
NCT02760602 TERMINATED
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
Eli Lilly and Company n=26
NCT01900665 TERMINATED
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Eli Lilly and Company n=2,129
NCT01127633 TERMINATED
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
Eli Lilly and Company n=1,457
NCT01931566 TERMINATED
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
Takeda n=3,494
NCT03620253 TERMINATED
Modafinil's Effects on Cognition in Remitted MDD
Unity Health Toronto n=9
NCT01561053 COMPLETED
A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease
Instituto Grifols, S.A. n=347
NCT02284906 TERMINATED
AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease
Takeda n=40
NCT03542656 COMPLETED
Application of Amyloid PET in Cerebral Amyloid Angiopathy
National Taiwan University Hospital n=160
NCT01953601 TERMINATED
Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)
Merck Sharp & Dohme LLC n=1,454
NCT03010865 WITHDRAWN
Sodium Butyrate For Improving Cognitive Function In Schizophrenia
Shanghai Mental Health Center
NCT01299766 COMPLETED
Preventing Cognitive Decline in African Americans With Mild Cognitive Impairment
Thomas Jefferson University n=221
NCT00838110 COMPLETED
A Phase 3 Study To Evaluate The Safety And Tolerability Of Dimebon Patients With Mild To Moderate Alzheimer's Disease
Pfizer n=742
NCT02585934 COMPLETED
Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study
Axovant Sciences Ltd. n=1,315
NCT01283750 COMPLETED
Maximizing Independence at Home (MIND at Home)
Johns Hopkins University n=303
NCT01739348 TERMINATED
An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738)
Merck Sharp & Dohme LLC n=2,211
NCT02317250 WITHDRAWN
Molecular Cerebral Imaging in Incipient Dementia (MCI-ID) II
University of California, Los Angeles
NCT02293915 COMPLETED
An Efficacy and Safety Study of Sodium Oligo-mannurarate (GV-971) Capsule for the Treatment of Alzheimer's Disease
Shanghai Greenvalley Pharmaceutical Co., Ltd. n=818
NCT02079246 COMPLETED
Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease
H. Lundbeck A/S n=1,463
NCT02550665 COMPLETED
Optimal Dose Escalation Strategy to Successful Achievement of High Dose Donepezil 23mg
Asan Medical Center n=176
NCT02928445 TERMINATED
Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension
Axovant Sciences Ltd. n=240
NCT01689233 COMPLETED
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
TauRx Therapeutics Ltd n=800
NCT01689246 COMPLETED
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
TauRx Therapeutics Ltd n=891
NCT01626378 COMPLETED
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
TauRx Therapeutics Ltd n=220
NCT02374567 TERMINATED
Pharmacovigilance in Gerontopsychiatric Patients
Hannover Medical School n=407
NCT01670526 COMPLETED
Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI
VA Office of Research and Development n=94
NCT02006641 COMPLETED
Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil
H. Lundbeck A/S n=858
NCT02006654 COMPLETED
Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor
H. Lundbeck A/S n=734
NCT02168920 TERMINATED
Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type
Otsuka Pharmaceutical Co., Ltd. n=150
NCT01955161 COMPLETED
Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil
H. Lundbeck A/S n=933
NCT01219244 COMPLETED
Effects of Dietary Interventions on the Brain in Mild Cognitive Impairment (MCI)
Charite University, Berlin, Germany n=330
NCT01047254 COMPLETED
Bupropion for the Treatment of Apathy in Alzheimer's Dementia
University Hospital, Bonn n=110
NCT01973400 COMPLETED
Neuroprotection by Tocotrienols in Type 1 and Type 2 Diabetes Mellitus
Universiti Sains Malaysia n=300
NCT01883648 TERMINATED
Study to Evaluate Coconut Oil for Alzheimer's Disease
University of South Florida n=21
NCT02035982 COMPLETED
Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease
Sunnybrook Health Sciences Centre n=40
NCT01404169 COMPLETED
A 24-weeks, Multi-center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease
Eisai Limited n=260
NCT02017340 COMPLETED
A Phase III Trial of Nilvadipine to Treat Alzheimer's Disease
Prof Brian Lawlor n=511
NCT01152216 TERMINATED
An Extension of the CONCERT Protocol (DIM18)
Medivation, Inc. n=672
NCT00675623 COMPLETED
A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease
Medivation, Inc. n=598
NCT00829374 COMPLETED
Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil
Medivation, Inc. n=1,003
NCT01409694 COMPLETED
Alzheimer's Disease - Input of Vitamin D With mEmantine Assay
University Hospital, Angers n=90
NCT01614886 COMPLETED
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
Novartis Pharmaceuticals n=216
NCT01325714 COMPLETED
Preventing Aggression in Veterans With Dementia
VA Office of Research and Development n=203
NCT00676143 TERMINATED
Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients
Pfizer n=1,100
NCT01020838 COMPLETED
Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology
Life Molecular Imaging SA n=218
NCT01577394 COMPLETED
Oculomotor Testing in the Differential Diagnosis of Dementia
Assistance Publique - Hôpitaux de Paris n=65
NCT01969136 TERMINATED
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
FORUM Pharmaceuticals Inc n=403
NCT01969123 TERMINATED
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
FORUM Pharmaceuticals Inc n=474
NCT02004392 TERMINATED
Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025
FORUM Pharmaceuticals Inc n=348
NCT01688128 COMPLETED
Efficacy of Ubiquitous SR-based Memory Advancement and Rehabilitation Training (U-SMART)
Seoul National University Bundang Hospital n=50
NCT01582854 COMPLETED
Efficacy and Safety of Actovegin in Post-stroke Cognitive Impairment (PSCI)
Takeda n=503
NCT00667810 TERMINATED
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
Pfizer n=901
NCT00998764 TERMINATED
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
Pfizer n=494
NCT01194128 COMPLETED
Facilitating Caregiver Adaptation to Patient Institutionalization
University of Pittsburgh n=217
NCT02327182 TERMINATED
Safety Study of MT-4666 in Subjects With Alzheimer's Disease
Tanabe Pharma Corporation n=117
NCT00743743 WITHDRAWN
Pilot Study of the Effects of Resveratrol Supplement in Mild-to-moderate Alzheimer's Disease
Medical College of Wisconsin
NCT02099890 COMPLETED
The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury
Brock University n=20
NCT02350738 COMPLETED
Effects of Multimodal Cognitive Enhancement Therapy (MCET) for Ealy Dementia
Ki Woong Kim n=64
NCT01667484 COMPLETED
Adderall XR and Processing Speed in Multiple Sclerosis (MS)
London Health Sciences Centre n=70
NCT00908492 COMPLETED
Supporting Caregivers of Persons With Dementia: A Pilot Study
McMaster University n=38
NCT00594568 COMPLETED
Effect of LY450139 on the Long Term Progression of Alzheimer's Disease
Eli Lilly and Company n=1,537
NCT00762411 COMPLETED
Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo
Eli Lilly and Company n=1,111
NCT01681602 COMPLETED
Effect of Physical Exercise in Alzheimer Patients
Rigshospitalet, Denmark n=200
NCT01451749 COMPLETED
Efficacy and Safety Study of Shenwu Capsule
North China Pharmaceutical Group Corporation n=324
NCT01035138 COMPLETED
A Study of Semagacestat for Alzheimer's Patients
Eli Lilly and Company n=180
NCT01028053 COMPLETED
Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease
GE Healthcare n=365
NCT01399125 COMPLETED
A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease
Novartis Pharmaceuticals n=501
NCT00539305 COMPLETED
Hormone and Information Processing Study
University of Washington n=22
NCT00898807 COMPLETED
Citalopram for Agitation in Alzheimer's Disease
JHSPH Center for Clinical Trials n=186
NCT01672827 COMPLETED
Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images
GE Healthcare n=276
NCT00996918 TERMINATED
A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients
Pfizer n=198
NCT00937352 TERMINATED
A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease
JANSSEN Alzheimer Immunotherapy Research & Development, LLC n=896
NCT01249196 COMPLETED
A Confirmatory Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease
SK Chemicals Co., Ltd. n=256
NCT01662882 COMPLETED
A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
Avid Radiopharmaceuticals n=48
NCT00679627 TERMINATED
A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease
Janssen Research & Development, LLC n=2,051
NCT00646269 COMPLETED
Efficacy Assessment of Three Non Pharmacological Therapies in Alzheimer's Disease
University Hospital, Bordeaux n=640
NCT00804271 COMPLETED
Memantine and Validation of a New Alzheimer's Disease Scale
Merz Pharmaceuticals GmbH n=487
NCT00904683 COMPLETED
Effect of LY2062430 on the Progression of Alzheimer's Disease
Eli Lilly and Company n=1,040
NCT00678431 COMPLETED
Randomized Trial of a Nutritional Supplement in Alzheimer's Disease
US Department of Veterans Affairs n=27
NCT00939783 TERMINATED
An Extension To The B1451027 Protocol To Evaluate The Long Term Safety And Tolerability Of Dimebon In Patients With Alzheimer's Disease
Pfizer n=649
NCT01142258 COMPLETED
Trazodone for Sleep Disorders in Alzheimer's Disease
Brasilia University Hospital n=40
NCT00912288 TERMINATED
A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease
Pfizer n=86
NCT01066546 TERMINATED
An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's Disease
Pfizer n=5
NCT00905372 COMPLETED
Effect of LY2062430 on the Progression of Alzheimer's Disease
Eli Lilly and Company n=1,000
NCT00857415 COMPLETED
Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the Brain
Avid Radiopharmaceuticals n=226
NCT00767091 COMPLETED
Study of Rivastigmine to Treat Parkinsonian Apathy Without Dementia
University Hospital, Lille n=40
NCT01183806 COMPLETED
Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients
Federal University of Bahia n=40
NCT01021696 COMPLETED
Pain in Patients With Dementia and Behavioural Disturbances
University of Bergen n=352
NCT01245530 COMPLETED
An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia
Whanin Pharmaceutical Company n=280
NCT00622128 COMPLETED
Preventing Aggressive Behavior in Demented Patients
US Department of Veterans Affairs n=10
NCT02813434 COMPLETED
Cerebral Amyloid Imaging Using Florbetapir (AV-45)
Centre Hospitalier Universitaire, Amiens n=92

Full Alzheimer's Disease Pipeline

Every trial across Phase 1–4, plus enrollment analytics. Sortable, filterable, exportable.

Unlock with Pro

Frequently asked

Common questions about the Alzheimer's Disease landscape

How many companies are developing Alzheimer's Disease treatments?
15 companies have active or registered Alzheimer's Disease programs in TheraRadar's competitive landscape (107 classified trials). The most active are Bristol-Myers Squibb, Eli Lilly, and Roche / Genentech.
What mechanisms of action are being developed for Alzheimer's Disease?
13 distinct mechanisms of action appear across the Alzheimer's Disease pipeline, including M1/M4 muscarinic agonist, Anti-amyloid (mAb), Undisclosed target, Anti-amyloid (BBB-shuttle), and Autologous adipose MSC.
What is the most crowded mechanism in Alzheimer's Disease?
M1/M4 muscarinic agonist is the most contested mechanism in Alzheimer's Disease, with 12 programs mapped to it.
Are there upcoming Alzheimer's Disease clinical readouts or FDA decisions?
Near-term Alzheimer's Disease catalysts include NIO752 (data readout, Jul '26); RO7269162 (data readout, Nov '26); Alzheimer Disease (AD) (data readout, Dec '26). Dates combine estimated trial primary-completion readouts and confirmed FDA decision dates.
Where does TheraRadar's Alzheimer's Disease landscape data come from?
Programs are derived from industry-sponsored ClinicalTrials.gov registrations (2008–present) and classified by mechanism of action using a curated rule set plus an LLM pipeline. Every cell links to its underlying trials, so each program is verifiable.
Is the Alzheimer's Disease heatmap free to use?
Yes — viewing and searching the Alzheimer's Disease heatmap is free. A TheraRadar Pro subscription adds advanced filters, row/column selection, and one-click export to PowerPoint, PDF, and CSV.
How this is built — methodology & limits

These grids are only as good as the data and the classification behind them — so here is exactly what goes in, what stays out, how every assignment is made, and where the limits are.

Where the data comes from

Every heatmap is built from the public ClinicalTrials.gov registry, via its official API — interventional drug and biologic trials with a start date of 2008 or later. The master index holds over 145,000 trials and is refreshed weekly (see the “updated” date on this page). A disease landscape draws only from the active, Phase 1–3, industry-sponsored slice of that index.

  • In scope: industry-sponsored trials in Phase 1, 2, or 3, with an active status (recruiting, active-not-recruiting, not-yet-recruiting, or enrolling by invitation). Phase 4 sits in the index but is left out of the landscapes.
  • Filtered out: deeply stale programs (a primary completion date more than two years past with no update to completed or terminated); basket trials and incidental mentions (a trial counts toward a disease only when that disease is genuinely the subject of study — not a secondary cohort, an organ-of-origin overlap, or a passing mention); and healthy-volunteer studies.

We do not exclude trials by sponsor geography. Where a sponsor is based in China, the program is flagged on the page rather than hidden, so you can weigh it yourself. An automated test fails the weekly refresh if the underlying index is more than 14 days old, so a published grid is never built on a stale index.

How a trial is matched to a disease

Matching uses a structured medical ontology, not keyword guessing, and is designed so that no trial is ever silently dropped — every trial that clears the filters gets a classification, even if that is just “Other.” It runs as an ordered sequence of steps, stopping at the first that applies:

  1. Healthy-volunteer studies are set aside as non-disease trials.
  2. Ontology match — each tracked disease is linked to its official identifiers in the standard medical taxonomy (MeSH), so a trial can be matched even when its text uses a synonym.
  3. Curated disease patterns — a hand-maintained library of over 150 disease-name patterns covers the more granular indications across oncology, hematology, infectious disease, cardiometabolic, immunology, and neuropsychiatry.
  4. Basket guard — a trial matching four or more distinct diseases, or carrying explicit basket language (“tumor-agnostic,” “all solid tumors,” “pan-cancer”), is grouped into a single advanced-solid-tumor category rather than over-counted across every cancer it touches.
  5. Therapeutic-area roll-up — a trial with no specific match, but which the taxonomy still places under a broad area, is assigned to that area (“Oncology — other,” “Immunology — other,” …), checking cancers first so a site-specific tumor isn’t filed under its anatomical system.

A “drop-if-parent-present” rule keeps a generic name from drowning out a subtype: a trial matching both lupus and lupus nephritis is reported only as lupus nephritis. Internal abbreviations are translated to the plain disease names used across the site (for example, “CRC” becomes “Colorectal Cancer”), and the same classifier is shared by every heatmap, so the same trial always maps to the same disease wherever it appears.

How a drug is matched to its mechanism

Mechanism of action is the hardest part to get right, so it is assigned in layers — leaning on curated and public data first, with AI as a last resort:

  1. Curated rulebook (first). A rulebook we maintain — over 600 drug-to-mechanism rules — is checked first, matching on drug names, trial acronyms, sponsor trial identifiers, and intervention lists. First match wins, which stops a combination trial from being counted several times.
  2. Public molecular-target data. Where no rule applies, each intervention’s target is looked up in a public target database, with verbose or gene-symbol labels normalized into consistent short forms so one target isn’t split across several columns.
  3. Standard-of-care backbones. A small set of rules recognizes common combination scaffolds (checkpoint-inhibitor monotherapy, standard chemotherapy regimens, established standard-of-care agents) so they aren’t mistaken for the experimental arm.
  4. AI as a last resort, then cross-checked. Only for genuinely opaque sponsor code-names that none of the first three steps can resolve do we ask an AI model to propose a mechanism — applied only above a fixed confidence bar, then automatically cross-checked against the sponsor’s own pipeline page. Where AI and the sponsor agree, the program is marked sponsor-verified. Where they contradict, the label is discarded entirely — not shown, not counted.

New mechanism rules are independently double-verified before they’re trusted — a second, adversarial pass set up to disprove the first — and each is checked so it can’t mislabel an unrelated trial. Drugs whose mechanism isn’t publicly disclosed are shown openly as “Emerging — not yet disclosed” rather than guessed at: for a tool meant to support real decisions, “we don’t yet know” is a more trustworthy answer than a confident guess.

Where AI is used — and where it isn’t

The disease and mechanism matching above is driven first by deterministic rules and public ontologies, not AI. AI plays three bounded, disclosed roles: (1) an optional extra check that a trial genuinely studies the disease, on top of the ontology match; (2) inferring a trial’s treatment setting on the competitive grids when the rules don’t cover it, only above a fixed confidence bar; and (3) the last-resort mechanism step above, always cross-checked against the sponsor’s disclosures. Wherever an AI label reaches a cell, the page marks it (⚙️ or ✅) — AI is never the silent, sole source of what you see.

What the on-page markers mean

  • ✅ Sponsor-verified — AI proposed the mechanism and it matched the sponsor’s own pipeline page. High-trust.
  • ⚙️ AI-classified — AI proposed it above the confidence bar but it has not yet been cross-checked against the sponsor. Useful; verify before citing. It never means a person reviewed it.
  • ⚡ First-in-class — the mechanism hasn’t appeared in any other disease landscape we’ve built. This reflects the scope of landscapes published so far (the tooltip lists exactly which were scanned), not an absolute claim about the whole market.
  • 🌱 First-in-indication — the only program competing on that mechanism within this disease.
  • 🆕 NME candidate — the interventions match no drug in our approved-drug index, suggesting a new molecular entity. The index is incomplete — a signal, not a regulatory fact.
  • 🔗 Combination · 👶 Pediatric · 🔥 Hot (readout within six months) · ⏳ Stale (completion date passed but still marked active — often a stalled program).

Sponsor names are resolved through a curated parent/subsidiary map; unrecognized sponsors appear under their raw registry name. The registry records the sponsor at a trial’s inception, so names are as originally filed and may not reflect later acquisitions. To keep large grids legible, mechanisms with a single program are listed separately rather than crowding the main grid, and very small players are listed below it — presentation choices only; nothing is removed from the underlying counts.

How we score programs — “what’s about to move”

Each program carries a 0–100 score that deliberately ranks imminence over raw stage — the most decision-relevant signal on a competitive grid. It is the sum of:

  • Clinical phase — up to 40 points (Phase 3 = 40, Phase 2 = 25, Phase 1 = 10).
  • Readout proximity — up to 60 points (next readout <6 months = 60, 6–12 months = 45, 1–2 years = 30, distant = 5).
  • Stale penalty — the score is halved if a trial is past its expected readout but still listed as active.

Cell colour on the grid is driven by this score, so a Phase 2 program about to read out can — correctly — outrank a dormant Phase 3 one. It answers “what’s about to move,” not just “what’s furthest along.”

What each grid plots

  • Indication landscape (this page) — one disease — companies (rows) × mechanism of action (columns): who is competing, and on what mechanism.
  • Company portfolio — one company — diseases (rows) × mechanism (columns): where it is active, and what it is betting on.
  • MOA platform — one mechanism family — drugs (rows) × diseases (columns): who is working on this class, and where.
  • Competitive landscape — one disease — mechanism (rows) × clinical setting (columns), aggregated across companies; setting columns are tailored per disease (e.g. lines of therapy in oncology; biologic-naïve vs. biologic-experienced in IBD).

What we don’t claim

  • First-in-class is editorial, not absolute — “not seen in the landscapes we’ve built,” not “novel across the industry.”
  • NME candidate is a signal, not a filing — absent from our (incomplete) approved-drug index.
  • Disease matching is automated and not exhaustively validated per disease — ontology and pattern matching can occasionally include or miss a trial.
  • AI-classified mechanisms are machine-proposed — unconfirmed unless they also carry ✅.
  • Sponsor names are as-filed and may lag current ownership.
  • Grids are as fresh as their last rebuild from the weekly index — no faster continuous refresh is claimed.

Data: ClinicalTrials.gov v2 API + FDA Drugs@FDA (approved-drug index). Spot an error? [email protected].

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only